Protalix Biotherapeutics (PLX)

$1.09 0.01 (0.46%)

20:00 EDT PLX Stock Quote Delayed 30 Minutes

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Apr 29, 2021

Good morning! We're getting ready for another day of trading with a list of the top pre-market stock movers for Thursday.

PLX Stock: Why Protalix BioTherapeutics Is Plunging 40% Today

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Volume:

Previous Close -

Market Cap 51.06M

PE Ratio -2.05

EPS -0.53

Volume (Avg. Vol.) 17,329

Day's Range $1.07 - $1.09

52-Week Range $0.70 - $2.00

Dividend & Yield N/A (N/A)

PLX Stock Predictions, Articles, and Protalix Biotherapeutics News

From the Web

Earnings Scheduled For May 16, 2022

From Benzinga May 16, 2022

Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.

Protalix Shares Surge After Encouraging Topline Data From Another Fabry Disease Trial

From Benzinga Apr 4, 2022

10 Most-Searched Tickers On Benzinga Pro In April: Musk Mania, Apple Drops, Several Newcomers Move Up

From Benzinga May 2, 2022

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the most-searched-for stocks on Benzinga Pro in the month of April.

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More

From Benzinga Apr 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

68 Biggest Movers From Yesterday

From Benzinga Apr 5, 2022

Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation. Aterian, Inc. (NASDAQ: ATER) shares...

Why Protalix BioTherapeutics Stock Is Soaring

From Benzinga Apr 4, 2022

Protalix BioTherapeutics Inc (AMEX:PLX) shares are surging Monday after the company said its Phase 3 trial for the treatment of Fabry disease met its primary endpoint. Fabry disease is an inherited disease resulting in progressive accumulation of abnormal deposits of a fatty substance in blood vessel walls throughout a person's body.